Preexisting computerized databases are potentially valuable sources of epidemiologic data. Since such databases are infrequently created specifically for etiologic research, data may be available for the exposure of interest and, through record linkage, for the endpoint of interest, but lacking for potential confounders. Because of the size of these databases, two-stage sampling is an efficient alternative to surveying the entire study population for confounder data. At stage 1, information on exposure and disease status is obtained for the entire study population. Confounder data are collected for probability-selected subsamples at stage 2. Logistic regression is performed on the stage 2 sample, with the parameter estimates and variances appropriately corrected to account for the stage 1 data. In this paper, the authors present methods for determining the required stage 2 sample size in the case of categorical exposure and confounding variables. Sample size tables, power curves, and a computer program have been produced to accommodate a binary exposure and a single binary confounder. With the increasing availability of preexisting yet incomplete databases, the potential for use of two-stage sampling will greatly increase in the future. This investigation provides a basis for estimating the number of participants to sample for the collection of confounder data at the second stage.
Many computerized data sources are potentially useful for epidemiologic research. Examples include physician claim files, hospital separation records, prepaid insurance plan databases, and occupational records. Studies using these databases can often be conducted more quickly and at a lower cost than those involving primary data collection. Unfortunately, such databases were seldom established with a view toward etiologic research. Although data on the exposure of interest may be available, with data on the endpoint of interest obtainable through record linkage, data on extraneous variables which could potentially confound the exposure-disease association are typically unavailable. The cost of surveying the entire study population may be prohibitive. A cost-effective alternative is to collect confounder data on a subset of the original study population-an approach which has been termed "two-stage sampling" (1-4), since information pertaining to the crude and covariable-adjusted exposure effects is obtained in two separate phases of the investigation.
For efficiency, stage 2 sample selection is typically based jointly on exposure and disease status. Although methods for analyzing two-stage data exist (1, 3, 4) , issues of sample size estimation have not been explicitly addressed. The objective of this article is to provide a method for deciding on the number of subjects to be selected at the second stage of a two-stage study.
EXAMPLES
Consider a hypothetical occupational cohort study of railway workers. Information on diesel exhaust exposure for cohort members could be estimated on the basis of employment histories. The cancer incidence experience of the cohort could be determined through linkage to vital statistics and cancer registry databases. However, the validity of any association would be compromised by the lack of information on smoking, since exposure might vary directly with smoking prevalence. If smoking data were not collected a priori, two-stage sampling could enhance the study's validity while negating the need to survey the entire cohort.
It was during the development of a protocol for a Canadian pharmacoepidemiologic study that the need for work on sample size calculations for two-stage studies was discovered. The investigation sought primarily to evaluate the effect of nonsteroidal antiinflammatory drugs and antidepressants on the risk of breast cancer. Information on prescription medication history and various demographic factors was obtained using data from a provincial health organization. Case ascertainment was accomplished through linkage to the provincial cancer registry. However, the investigators required data on several variables which could potentially confound the association of interest, such as ages at menarche and menopause, family history, nulliparity, obesity, and alcohol consumption. Efforts to estimate the cost of interviews at the second stage were thwarted by the unavailability of stage 2 sample size estimates.
TWO-STAGE SAMPLING METHOD
The data layout for a two-stage study is depicted in figures 1 and 2. At stage 1, the investigator obtains data on exposure and disease status. This first-stage sample could represent the traditional case-control, historical cohort, or cross-sectional study. At stage 2, confounder data are collected for a subset of the stage 1 participants. For efficiency (i.e., inverse of variance or information per sample member), a "balanced" design is often utilized at stage 2. That is, to the extent possible, equal numbers of stage 1 members are selected from each cell of the cross-tabulation of disease and exposure. When a cell has been exhaustively sampled, the remaining cells are sampled equally. This sampling algorithm, also referred to as "equal alloca- tion," is usually more efficient than random, diseasebased, or exposure-based stage 2 sampling. Its efficiency derives from sampling fractions that are inversely proportional to cell size, exploiting the fact that observations from small groups contribute, on average, more information than those from large groups. The reason for the increased efficiency can be understood heuristically from Woolf s formula for the variance of the logarithm of the odds ratio (OR) (5).
ANALYSIS OF TWO-STAGE DATA Preliminary issues
Assume that disease status (D) is dichotomous (1 = present, 0 = absent), exposure (E) is categorical with J levels (0,..., / -1), and there exists one confounder (C) which is categorical with K levels (0, ... , K -1), with 0 serving as the reference level for both exposure and confounder. Let N tJ denote the number of subjects in the stage 1 sample with D -i and E = j, where N = L^jNij. Let n t j k be the number of stage 2 sample members with D = i, E = j, and C = k, where n 2 = XjXjXktiijk, and ny = S^n,-^. Assume that disease incidence can be described by a multiplicative model. That is,
where {£,} are indicator variables such that Ej = 1 when E = j and 0 otherwise, with the {C k } similarly defined.
Data analysis
As outlined by Breslow and Cain (3, 4) , to analyze two-stage data using logistic regression, parameter estimates are obtained from the stage 2 data. These estimates and their corresponding covariance matrix are corrected to account for the information provided by the stage 1 data and the biased stage 2 sampling mechanism, the bias having been introduced by exposure-dependent sampling. The corrected OR, contrasting disease incidence between subjects with E = j versus E = 0 is given by OR ; = where "(2)" denotes estimation based on the stage 2 data alone and Sy = n^/Ny denotes the sampling fractions. Thus, the adjusted OR, is OR,-(2) scaled by the cross-product of the sampling fractions for the 2 X 2 table relating disease status and exposure levels 0 and j, algebraically similar to the correction for selection bias described by Kleinbaum et al. (6) . The vari- ance of the corrected exposure parameter estimate is given by
where V 2 (f5j) log i Stic is the variance from the logistic regression based on the stage 2 data alone. Because the correction factor is nonnegative, the correction reduces the variance of the exposure parameter estimate, since it incorporates additional information available on the crude association between exposure and disease. Breslow and Cain provide other relevant formulae with respect to the analysis of two-stage data (4) and their derivations (3).
SECOND-STAGE SAMPLE SIZE AND POWER

Background
For ease of presentation, we assume that exposure is binary (1 = present, 0 = absent). The null hypothesis, H o : OR = e& = 1, is tested against the alternative hypothesis, H A : OR = e p ¥= 1. The presence of only one nonreferent exposure level precludes the need to subscript /3 or OR. Our goal is to estimate the required stage 2 sample size (n 2 ) such that we have power of at least (1 -e) against a given value for OR =£ 1, where e refers to type II error. Thus, we seek the minimum n 2 such that the following inequality is satisfied:
where $ is the cumulative distribution function for the standard normal distribution, Za/ 2 denotes the 100(1 -a/2) percentile of the standard normal distribution corresponding to the type I error of size a (two-sided), z e is similarly defined for the type II error of size e, and the subscripts "0" and "A" refer to the sampling distribution for the logistic regression coefficient, /3, under H o and H A , respectively.
Variances
As equation 4 indicates, to estimate power we must project V(/3) under the null and alternative hypotheses. For each scenario, we can write this variance as the sum of the variability associated with the first and second stages. 
The variance component associated with the logistic regression-based parameter estimate is given by
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where the circumflexes indicate fitted values under the logistic model. Thus, the functional units of this variance {v k } are sums of the reciprocals of the frequencies in the confounder-stratum-specific 2X2 tables of fitted values. The regression-based variance has the same form as that obtained by Woolf s method, with the cell counts replaced by fitted values under the model. For V 2 (/3/)i O gistic f°r a multilevel exposure, replace n nk with n ijk . In the case of more than one confounder, the summation is over all possible confounder level combinations. Thus, V(/3) can be completely specified in terms of the crude 2X2 tables at stages 1 and 2 and the confounder-stratum-specific fitted 2X2 tables at stage 2. A method of calculating these expected cell entries is outlined in the Appendix.
Having dealt with the variances, we can calculate power directly for a fixed value of n 2 and a given allocation on the ity. However, iteration is required to find the minimum n 2 for a prespecified level of power when the balanced design is employed, since the sampling fractions, and hence the adjustment to the variance, are unknown until n 2 is known. The sampling fractions are known in advance only when n^ -/i 2 /4 (i.e., « 2 ^ min{fy,} X 4).
RESULTS AND ILLUSTRATION
Power with a given sample size Figure 3 provides an example of a power calculation for a fixed stage 2 sample size for a binary exposure and confounder, in the context of a case-control study with a stage 1 sample in which the number of cases and controls is prespecified and the stage 2 sample size is fixed in advance at n^ -600. If one collected confounder information for all subjects, the power would be approximately 92 percent. As is shown, approximately 90 percent of the power available from the corresponding single-stage design was retained even though the confounding was relatively strong (crude OR = 2.14; OR adjusted for C: e p = 1.5) and only one fifth of the study population was sampled at stage 2, exemplifying the efficiency of two-stage sampling using the balanced design.
Sample size for a given power Table 1 lists the n 2 s required in order to achieve 90 percent power for various case-control studies under the balanced design. The user must anticipate the incidence density ratios for the exposure and the confounder; the prevalences of the exposure and the confounder (p E and p c , respectively); and the degree of association between E and C, quantified by previous authors (3, 4) by the "control odds ratio," 8, which is the cross-product of cell prevalences in the 2 x 2 table relating E and C in the source population from which the cases arose (i.e., 6 = PuPoo'PioPoi)-
Determinants of power/sample size
The factors affecting the power of a stage 2 sample were examined. Although the results displayed in figures 4 and 5 pertain to particular ranges or values of n 2 and specific target population parameters, the observed trends apply generally. Power increases greatly with the number of cases collected at stage 1, although, naturally, marginal returns eventually diminish ( figure 4, top left panel) . There appears to be little gain in stage 2 power by sampling more than four controls per case at stage 1 (figure 4, top right). The strongest determinant of power is the exposure odds ratio (figure 4, bottom left), which has a much greater impact on power than the confounder odds ratio (figure 4, bottom right) . The impact on study power of the exposure prevalence exceeds that of the confounder ( figure 5, top panel) . The values of exposure or confounder prevalence at which power is minimized and maximized depend on the values of the remaining parameters, although the curve is consistently U-shaped for confounder prevalence and takes an inverted U shape for exposure prevalence. Stage 2 power is a decreasing function of the degree of association between exposure and confounder (figure 5, 122.1 (111.3) 00 FIGURE 3. Example of power calculation for a two-stage study. A two-stage case-control study is planned to evaluate the effect on disease incidence (D) of an exposure (£) recorded on a binary scale after adjustment for a single binary confounder (C). The following quantities are known or estimated: cases {N-, = 1,000), controls (A/ o = 2,000), exposure prevalence (p E = 10%), confounder prevalence (p c = 30%), exposure odds ratio {e p = 1.5) (crude exposure odds ratio = 2.1), confounder odds ratio (e 7 = 3.0), and stage 2 sample size (fixed in advance) {n 2 = 600). The {E,C) distribution in the source population is described in section a, with 0 = (0. bottom). Overall, the exposure attributes (odds ratio and prevalence) have the greatest impact on the power of the sample selected at stage 2, although confounder prevalence, the confounder odds ratio, and the control odds ratio also play a large role. The effect on power of varying one of these parameters depends on the values of the others. These results parallel those for the single-stage design, except that the stage 2 sample size required to achieve a fixed level of power in the two-stage design is more sensitive to the confounder attributes relative to that for the one-stage design (data not shown).
Available tools
Two tools for stage 2 sample size considerations have been developed for the case of a binary exposure and a single binary confounder. The first is a set of 
10%
30% 50% * Stage 2 sample size required to detect an exposure odds ratio (OR) of eP = 1.5 with 90% power and type I error of a = 0.05 (two-sided).
t A case-control study {N. cases and W o controls at stage 1) designed to evaluate the effect of exposure recorded on a binary scale, witn adjustment for a single binary confounder with the following quantities anticipated: exposure prevalence = pp confounder prevalence = p^, exposure OR = eP, confounder OR = ei, and (£,C) crossproduct ratio = 8. tables and power curves, generated by a program written in SAS (SAS Institute, Cary, North Carolina), which provides the required n 2 for either 80 percent or 90 percent power. The second is an executable program (source code written in C) which can calculate either power for a given n 2 or the minimum n 2 needed to achieve a prespecified level of power. The relevant tables and software for this procedure are available from the first author upon request.
DISCUSSION
Although methods for analyzing two-stage data have been described, issues pertaining to sample size estimation have not been explicitly addressed. Here we provide a basis for determining an appropriate number of participants to select at the second stage when the exposure and confounders are categorical, and we have produced tables and software with which to accommodate a binary exposure with a single binary confounder. Two-stage sampling was initially proposed for epidemiologic research independently by both White (1) and Walker (2) in 1982. Each presented a stratified analysis with a binary exposure. White derived the variance for the covariable-adjusted odds ratio, with estimation equivalent to weighted least squares. Breslow and Cain (3, 4) extended White's methods to incorporate multilevel and continuous variables using a pseudo-likelihood approach, with analysis based on logistic regression. Zhao and Lipsitz (7) have proposed a family of 12 two-stage sampling designs, of which those considered in this report constitute special cases. Wacholder et al. (8) coined the phrase "partial questionnaire design," wherein basic data are collected from all study participants through use of a brief
APPENDIX Expected Cell Entries
Stage 1. Assume that the numbers of diseased and nondiseased subjects at stage 1 are known, and that the data layout for the study population follows that of table 1. Under a multiplicative model, as in equation 1, with no interaction, the expected entries of the 2 X J table at stage 1 are:
Stage 2. With the n,y known, the expected cell entries for the 2 X / X K table at stage 2 are given by:
